Citizens JMP raised the firm’s price target on Nuvation Bio (NUVB) to $8 from $6 and keeps an Outperform rating on the shares. Nuvation Bio reported Q4 financial results and highlighted 204 new Ibtrozi starts in Q3, the analyst tells investors in a research note. The launch trajectory is exceeding expectations and is already outpacing ROS1 launches in recent memory, Citizens says.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: